Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
XTL Biopharmaceuticals Ltd. Sponsored ADR ( (XTLB) ) has shared an announcement.
In a recent development, XTL Biopharmaceuticals Ltd. announced on November 19, 2024, that as part of a settlement agreement with the chief executive officer of its subsidiary, The Social Proxy Ltd., and its previous shareholders, the shareholders will now elect one director to XTL’s Board instead of two as initially agreed. Following this, on February 3, 2025, directors Tal Klinger and Yair Redl, who were appointees from The Social Proxy, resigned from the Board, although their resignations were not due to disagreements with XTL’s management. This leaves the Board with no current representatives from The Social Proxy, but the shareholders still retain the right to appoint one director.
More about XTL Biopharmaceuticals Ltd. Sponsored ADR
XTL Biopharmaceuticals Ltd. is an IP portfolio company focused on developing treatments for Lupus disease (SLE) through its IP surrounding hCDR1. It owns The Social Proxy Ltd., a web data AI company, which offers a unique ethical proxy data extraction platform for AI and BI applications. XTL is listed on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
YTD Price Performance: -19.34%
Average Trading Volume: 12,742
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.4M
For a thorough assessment of XTLB stock, go to TipRanks’ Stock Analysis page.
